Compare Stocks → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:BFRINASDAQ:BXRXNASDAQ:CINGNASDAQ:CMRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.99-2.9%$1.49$0.61▼$13.42$5.04M0.45482,009 shs21,700 shsBXRXBaudax Bio$0.02+7.4%$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,800 shsCINGCingulate$0.72+0.7%$0.87$0.65▼$21.20$4.37M-0.93310,351 shs107,500 shsCMRAComera Life Sciences$0.03+0.7%$0.03$0.02▼$0.74$861K0.0819,626 shs100 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%-3.88%-21.43%-18.18%-88.91%BXRXBaudax Bio0.00%0.00%0.00%0.00%-96.04%CINGCingulate0.00%+3.11%-5.02%-41.71%-96.38%CMRAComera Life Sciences0.00%+23.35%+32.08%-44.00%-93.51%It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolutionMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.0577 of 5 stars3.55.00.00.00.60.01.3BXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate1.4414 of 5 stars3.23.00.00.00.04.20.0CMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera3.00Buy$18.001,718.18% UpsideBXRXBaudax BioN/AN/AN/AN/ACINGCingulate2.33Hold$8.001,006.81% UpsideCMRAComera Life SciencesN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$34.07M0.15N/AN/A$3.16 per share0.31BXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CINGCingulateN/AN/AN/AN/A($5.88) per shareN/ACMRAComera Life Sciences$630K1.37N/AN/A($0.37) per share-0.08Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$13.10N/AN/AN/A-69.44%-1,390.99%-85.45%8/9/2024 (Estimated)BXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACINGCingulate-$23.53MN/A0.00∞N/AN/AN/A-448.18%8/12/2024 (Estimated)CMRAComera Life Sciences-$18M-$0.49N/A∞N/A-904.00%N/A-297.91%N/ALatest CING, BXRX, BFRI, and CMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024BFRIBiofrontera-$1.63-$1.85-$0.22-$0.82$11.52 million$7.91 million5/8/2024Q1 2024CINGCingulate-$2.20-$0.60+$1.60-$0.60N/AN/A3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABXRXBaudax BioN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.440.94BXRXBaudax BioN/A0.070.07CINGCingulateN/A1.211.21CMRAComera Life SciencesN/A0.900.90OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BXRXBaudax Bio9.05%CINGCingulate41.31%CMRAComera Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.21%BXRXBaudax Bio0.10%CINGCingulate21.79%CMRAComera Life Sciences8.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera835.09 million5.08 millionNo DataBXRXBaudax Bio952.46 million52.41 millionNot OptionableCINGCingulate136.05 million4.73 millionNot OptionableCMRAComera Life Sciences1230.74 million28.00 millionNot OptionableCING, BXRX, BFRI, and CMRA HeadlinesRecent News About These CompaniesMay 13, 2024 | msn.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceJanuary 31, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionDecember 6, 2023 | msn.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Announces Process Exploring Strategic AlternativesNovember 26, 2023 | benzinga.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 18, 2023 | knoxdaily.comComera Life Sciences Holdings Inc [CMRA] stock for 1,049,897 USD was acquired by Cherington CharlesNovember 14, 2023 | finance.yahoo.comComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 9, 2023 | msn.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsNovember 8, 2023 | knoxdaily.comComera Life Sciences Holdings Inc [CMRA] Insider Activity: An Update for InvestorsOctober 18, 2023 | knoxdaily.comInvesting in Comera Life Sciences Holdings Inc (CMRA): What You Must KnowOctober 18, 2023 | finance.yahoo.comComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 16, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceOctober 13, 2023 | knoxdaily.comComera Life Sciences Holdings Inc [CMRA] 10% Owner makes an insider purchase of 2,053,789 shares worth 1.05 million.September 13, 2023 | benzinga.comMassive Insider Trade At Comera Life SciencesSeptember 12, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | finance.yahoo.comComera Life Sciences Announces the Completion of $4.1 Million Private PlacementNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Options Strategies to Protect Your Stocks in a Falling MarketBy Jea Yu | June 5, 2024View 3 Options Strategies to Protect Your Stocks in a Falling MarketSell the Meme Stocks in May and Go Away?By Ryan Hasson | May 22, 2024View Sell the Meme Stocks in May and Go Away?GameStop Roars Near 100% as Roaring Kitty Posts Massive PositionBy Ryan Hasson | June 3, 2024View GameStop Roars Near 100% as Roaring Kitty Posts Massive PositionMedtronic Dips: Is Now the Time to Buy?By Thomas Hughes | May 24, 2024View Medtronic Dips: Is Now the Time to Buy?Macy's Q1 Turnaround Takes Shape as Consumers ShiftBy Jeffrey Neal Johnson | May 22, 2024View Macy's Q1 Turnaround Takes Shape as Consumers ShiftCompany DescriptionsBiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Baudax BioNASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.CingulateNASDAQ:CINGCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Comera Life SciencesNASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
